Treatment of Hypopituitarism in Pituitary Apoplexy

Pituitary apoplexy is an acute, life-threatening emergency that can precipitate sudden hypopituitarism and requires prompt clinical recognition and urgent management.

Clinical Scenario Pituitary apoplexy — acute infarction, hemorrhage, and/or necrosis of the pituitary gland — presents as rapid-onset severe headache and may be accompanied by vomiting, fever, meningismus, visual disturbances, and altered mental status. Hypopituitarism arising in this context carries significant risk of mortality from acute adrenal insufficiency.

Management Approach (partial) The cornerstone of acute management is glucocorticoid therapy, initiated urgently to address the risk of life-threatening adrenal insufficiency while laboratory assessment of pituitary function is underway. The full protocol specifies how and when to transition to maintenance therapy. Full regimen, route, and sequencing available below →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1210/jc.2016-2118

Pituitary apoplexy is a life-threatening acute pituitary infarction, hemorrhage, and/or necrosis presenting as rapid onset headache and may include vomiting, fever, meningismus, vision abnormalities, and changes in mental status.

Because acute AI is a major cause of mortality, we recommend GC therapy until a laboratory diagnosis is established and the patient maintains normal pituitary function.

When patients cannot tolerate oral medications, they should begin with a 100–200 mg iv HC bolus followed by 2–4 mg/h by continuous infusion or 50–100 mg injections every 6 hours.

Clinicians should quickly taper HC as indicated and initiate standard oral maintenance doses.

Clinicians have also used high doses of dexamethasone to treat pituitary apoplexy.

View source ↗